BioLoomics Appoints Kurt Gish as Chief Scientific Officer to Advance Development of Improved ADCs

Former CSO of Trilo Therapeutics and Research Fellow at AbbVie joins to lead BioLoomics’ pipeline and combine lysosome targeting antibodies with ADCs

BOULDER, Colo. – BioLoomics, a biotechnology company that targets peptide-antibody chimeras to specific compartments inside of diseased cells, announced today that Kurt Gish, Ph.D., has joined as the Chief Scientific Officer. Dr Gish will focus on building the company’s pipeline of lysosomal targeting ADCs in oncology to overcome the limitations of poor tumor uptake, which hinders safety and efficacy across the ADC market.

“I’m thrilled to join such an innovative team and look forward to getting the best possible treatments to patients that so desperately need them. ”Post this

“Kurt is an impressive and accomplished scientist that sits at the intersection of ADCs, peptides, and target discovery/validation. He has a deep understanding of how improper spatial targeting of ADCs has limited the field. With his deep experience in the ADC space, I am confident that Kurt will be invaluable to advancing BioLoomics’s technology to build safer and more efficacious ADCs for both strategic partners and internal programs.” – Dr. Chapnick, CEO and Founder of BioLoomics.

Prior to BioLoomics, Dr. Gish served as Chief Scientific Officer and Founder of Trilo Therapeutics. At Trilo, he pioneered a novel DNA encoded library approach to build D-peptide conjugates to rival traditional ADC modalities. Prior to Trilo, Dr. Gish was an early pioneer in ADCs at AbbVie, investigating novel linkers and payloads, exploring the nature of antigen-independent toxicity, and driving two ADC programs into human clinical trials. He is the inventor on more than 25 issued US patents. Dr. Gish earned his Ph.D. in Biology from Stanford University and studied molecular immunology during his postdoctoral fellowship at DNAX Research Institute. He serves on the scientific advisory board of the Myeloma Investment Fund of the Multiple Myeloma Research Foundation.

“BioLoomics is developing incredible technology to deliver more therapeutic drug directly into cancer cells while minimizing systemic toxicity,” remarked Dr. Gish. “I’m thrilled to join such an innovative team and look forward to getting the best possible treatments to patients that so desperately need them.”

About BioLoomics

Headquartered in Colorado, BioLoomics is a preclinical stage biotechnology company pioneering directed evolution of antibody-peptide chimeras with programmable internalization and lysosome targeting. Lysosome targeted antibody-peptide chimeras have broad utility to elicit increased payload delivery mechanisms in the ADC therapeutic space. The company has raised a total of $10.1 million from top investors including Innovations Endeavors, Horizons Ventures, TechU Ventures, Boom Capital Ventures, BoxOne Ventures, GC&H, and Viswa Colluru.